Trial Profile
A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Solid Tumors
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs A01-IC01 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Hangzhou Converd
- 23 Mar 2018 New trial record